Can a simple nudge get ovarian cancer patients to the right specialist faster?
NCT ID NCT06451263
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This study tests whether a gentle reminder to doctors can increase referrals to gynecologic oncology for women with suspicious ovarian masses. Researchers will send a message to ordering providers within 48 hours of imaging results, encouraging them to refer patients. The study includes 20 women and compares results to past patients to see if the nudge helps more women see a specialist within 30 days.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Nudge (behavioral intervention)
- What this could lead to
- If successful, this could show that a simple reminder helps more patients see a specialist quickly, potentially improving ovarian cancer outcomes.
- What could go wrong
- This is a small pilot study with only 20 participants, so results may not apply broadly. It tests a process, not a treatment, so direct health benefits are uncertain.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
20 people
The number who actually took part.
- Started
-
Jan 2024
- Expected to finish
-
May 2027
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Female participants only
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Women ages 18 years or older * Adnexal mass identified on imaging (i.e., O-RADS 4 or 5 on ultrasound or MRI, Codex 4 or 5 on CT scan) ordered by Penn Medicine clinician Exclusion Criteria: * Known diagnosis of ovarian cancer * Patient already established in gynecologic oncology
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Fallopian tube cancer are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
University of Pennsylvania
Philadelphia, Pennsylvania, 19104, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can MRI and computer models predict how well cancer drugs reach tumors?
- Can a Patient's own immune cells fight ovarian cancer?
- Ovarian Cancer's spread: scientists probe abdominal fluid for clues
- New PET tracer aims to light up hidden cancer targets
- Can inhaled manganese make ovarian cancer immunotherapy hit harder?
- Can a pill shrink Hard-to-Treat ovarian tumors?